Xiaohong Chi

Long non‐coding RNA TPT1‐AS1 inhibits ferroptosis in ovarian cancer by regulating GPX4 via CREB1 regulation

AbstractBackgroundLong non‐coding RNAs (lncRNAs) play crucial roles in cellular processes, with dysregulation implicated in various diseases, including cancers. The lncRNA TPT1‐AS1 (TPT1 Antisense RNA 1) promotes tumor progression in several cancers, including ovarian cancer (OC), but its influence on ferroptosis and interaction with other proteins remains underexplored.MethodsIn this study, we employed a multi‐faceted approach to investigate the functional significance of TPT1‐AS1 in OC. We assessed TPT1‐AS1 expression in OC specimens and cell lines using RT‐qPCR, in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) assays. Functional assays included evaluating the impact of TPT1‐AS1 knockdown on OC cell proliferation, migration, invasiveness, and cell cycle progression. Further, we explored and validated the interaction of TPT1‐AS1 with other proteins using bioinformatics. Finally, we investigated TPT1‐AS1 involvement in erastin‐induced ferroptosis using Iron Assay, Malondialdehyde (MDA) assay, and reactive oxygen species (ROS) detection.ResultsOur findings revealed that TPT1‐AS1 overexpression in OC correlated with an unfavorable prognosis. TPT1‐AS1 knockdown suppressed cell proliferation, migration, and invasiveness. Additionally, TPT1‐AS1 inhibited erastin‐induced ferroptosis, and in vivo experiments confirmed its oncogenic impact on tumor development. Mechanistically, TPT1‐AS1 was found to regulate Glutathione Peroxidase 4 (GPX4) transcription via CREB1 (cAMP response element‐binding protein 1) and interact with RNA‐binding protein (RBP) KHDRBS3 (KH RNA Binding Domain Containing, Signal Transduction Associated 3) to regulate CREB1.ConclusionTPT1‐AS1 promotes OC progression by inhibiting ferroptosis and upregulating CREB1, forming a regulatory axis with KHDRBS3. These findings highlight the regulatory network involving lncRNAs, RBPs, and transcription factors in cancer progression.